International Society for Heart and Lung Transplantation

ISHLT Supports Research Funding for Advanced Heart and Lung Disease: Applications Open Now

Retrieved on: 
Tuesday, November 7, 2023
Survival, Quality of life (healthcare), VAD, Research, MCS, Lung transplantation, ECP, Immunomodulation, Mallinckrodt, International Society for Heart and Lung Transplantation, International Society, Patient, Heart failure, International Consortium of Investigative Journalists, Pharmaceutical industry, Dentistry

The ISHLT Foundation funds research, including grants like these, to improve treatment options and patient outcomes around the world.

Key Points: 
  • The ISHLT Foundation funds research, including grants like these, to improve treatment options and patient outcomes around the world.
  • The Foundation also funds improved access to care by funding professional education opportunities around the world.
  • ISHLT/ICCAC VAD Coordinator Career Development Grant: Providing support to a VAD coordinator for a quality improvement and/or research project.
  • ISHLT/OH Frazier Grant in MCS Translational Research: Supporting mechanical circulatory support (MCS) research.

Honor the Gift disputes CMS' claim that there is no change in Medicare coverage of blood tests for monitoring rejection in transplant patients

Retrieved on: 
Wednesday, September 27, 2023
Centers for Medicare & Medicaid Services, DNA, Gift, CMS, Honor walk, Rush University Medical Center, The Wall Street Journal, International Society for Heart and Lung Transplantation, Anxiety, Lung transplantation, Patient, Policy, International Society of Sculptors, Painters and Gravers, American Society of Transplantation, Health equity, Multimedia, Transplant, LCD, Associate, Government, George Washington University Hospital, Dialysis, Medicare, Congress, George Washington School, Medical director, Physician, Organ transplantation, Division, Democrat, Surgeon, Kidney, George Washington University School of Medicine & Health Sciences, Health, Longevity, House, Society, Macs, Biopsy, Transplant surgeon, Hospital, Pharmaceutical industry, Dentistry, MD

WASHINGTON, Sept. 27, 2023 /PRNewswire/ -- Honor the Gift, a coalition representing organ transplant patients across the nation, along with other allied leaders across the transplant field, respond to the Centers for Medicare & Medicaid Services' (CMS) press release stating that "neither CMS nor the Medicare Administrative Contractors (MACs) have made changes that affect patients' ability to have blood tests used to monitor for organ transplantation rejection covered when ordered by their physicians in medically appropriate circumstances."  

Key Points: 
  • The Honor the Gift coalition finds this statement inaccurate and contradicted by patients and physicians nationwide.
  • The changes announced on March 2, 2023, have alarmed transplant patients and clinicians across the nation, followed by an apparent decline in physician ordering of these vital blood tests1.
  • The Honor the Gift coalition and allies dispute this assertion – this is not a "clarification" but a change in coverage policy.
  • The concerns raised by patients, clinicians, and Congress emphasize the need for continued dialogue to restore longstanding Medicare coverage.

National transplant patient and physician groups ask President Joe Biden and HHS Secretary Xavier Becerra to: "Stop private contractors from rolling back Medicare coverage of non-invasive blood tests to detect transplant rejection"

Retrieved on: 
Thursday, September 21, 2023
Trauma, DNA, Gift, CMS, Society, HHS, Centers for Medicare & Medicaid Services, The Wall Street Journal, International Society for Heart and Lung Transplantation, Anxiety, Lung transplantation, International Society of Sculptors, Painters and Gravers, Health, End organ damage, Multimedia, LCD, USC, Gene expression profiling, Government, Lung, GEP, Patient, Democrat, American Society of Transplantation, Kidney, Heart failure, House, Center for Medicare and Medicaid Innovation, International Society, Pelvic floor dysfunction, United States Department of Health and Human Services, Transplant surgeon, Pharmaceutical industry, Health insurance, Dentistry, Medicare, MD, Transplant, Policy, D.C

WASHINGTON, Sept. 21, 2023 /PRNewswire/ -- Honor the Gift, a coalition representing organ transplant patients across the nation, along with other allied leaders across the transplant field, held a press conference, calling on President Joseph R. Biden and Health and Human Services (HHS) Secretary Xavier Becerra to stop the current attempt by private contractors to rollback Medicare coverage of safe, non-invasive molecular blood tests that can allow for the early detection of organ rejection.

Key Points: 
  • -- Paul Conway, AAKP
    Medicare coverage for these innovative blood tests became available for transplant patients starting in 2006, with coverage expanding in 20171.
  • The alternative for such blood tests is surgical biopsy procedures, which are more expensive, riskier, and burdensome.
  • See statements from American Society for Transplant Surgeons , American Society of Transplantation , and The International Society for Heart and Lung Transplantation .
  • This billing article was issued without allowing for public comment, including comments from the transplant patients who would be impacted.

CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance

Retrieved on: 
Wednesday, August 2, 2023
Research, Surgery, Genetics, Clinical Trials, Cardiology, Health Insurance, Biometrics, Health, Science, DNA, Biopsy, Stanford University, Embraer EMB 314 Super Tucano, GEP, Heart, Lung transplantation, Section, Palmetto, Biomarker, USC, Medicare, Journal, Publication, MD, Patient, Medicine, Heart failure, American College, Caregiver, FDA, International Society, International Society for Heart and Lung Transplantation, Pharmaceutical industry, Dentistry, Medical imaging

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance.
  • AlloMap Heart and AlloSure Heart are also covered by Medicare individually.
  • “Today is a major milestone for heart transplant care and for the use of multimodality technologies to improve patient outcomes with HeartCare,” said Reg Seeto, CEO and President of CareDx.
  • I want to thank MolDX for recognizing the critical clinical value of multimodality in heart transplant surveillance.”
    “Medicare’s coverage of HeartCare reflects the growing scientific evidence supporting its use for routine graft surveillance in lieu of a biopsy.

Submission Site for ISHLT 2024 Annual Meeting Abstracts Now Open

Retrieved on: 
Tuesday, August 1, 2023
Call, Heart, Abstract (summary), International Society for Heart and Lung Transplantation, Lung transplantation, Research, Doctor of Philosophy, Nursing, International Society, Dentistry, MD

Chicago, IL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) has opened abstract submissions for its 44th Annual Meeting & Scientific Sessions in Prague, Czech Republic on 10-13 April, 2024.

Key Points: 
  • Chicago, IL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) has opened abstract submissions for its 44th Annual Meeting & Scientific Sessions in Prague, Czech Republic on 10-13 April, 2024.
  • “Abstracts and presentations are the cornerstones of every ISHLT meeting,” said ISHLT2024 Scientific Program Chair, Göran Dellgren, MD, PhD.
  • The ISHLT welcomes submissions from all specialists engaged in treating advanced heart and lung disease, particularly those working on novel therapies.
  • For more information about ISHLT2024, and to see full details on the Call for Abstracts, visit ishlt.org/ishlt2024 .

ISHLT Names Prof. Dirk Van Raemdonck as Inaugural Editor-in-Chief for JHLT Open

Retrieved on: 
Wednesday, May 31, 2023
FERS, Checklist, FRCP, Thorax, International Society for Heart and Lung Transplantation, Lung transplantation, GOLD, Research, The Journal of Heart and Lung Transplantation, Doctor of Philosophy, Transplant, MD, Patient, UZ Leuven, Knowledge, Newcastle University, International Society, Microsoft Access, Pharmaceutical industry, Dentistry, Heart

Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) announces the appointment of Dirk Van Raemdonck, MD, PhD, FEBTS, FERS, as the inaugural Editor-in-Chief of JHLT Open, the Society’s new open access journal.

Key Points: 
  • Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) announces the appointment of Dirk Van Raemdonck, MD, PhD, FEBTS, FERS, as the inaugural Editor-in-Chief of JHLT Open, the Society’s new open access journal.
  • JHLT Open is a new journal complementing the venerable Journal of Heart and Lung Transplantation (JHLT), ISHLT’s flagship journal, which is ranked as the number one journal in transplantation by impact factor.
  • "I am deeply honored to be appointed as the Editor-in-Chief for JHLT Open," said Prof. Van Raemdonck.
  • While JHLT Open will be general in content, it will also create opportunities for special virtual issues and programs that highlight specific areas of interest.

CareDx Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, May 10, 2023
Health Technology, Genetics, Health, Other Health, TRIO, Lung transplantation, American Society of Transplantation, Digital Solutions, Ann Harrison (lung transplant recipient), GAAP, Transplant, Medicare, Net, EBITDA, Patient, Ecosystem, International Organization (journal), International Society for Heart and Lung Transplantation, Society, International Society, Caregiver, Impaction, Transplant surgeon, Pharmaceutical industry, Bookkeeping, Bank, Dentistry

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023.
  • Non-GAAP net loss was $5.8 million in the first quarter of 2023, compared to a non-GAAP net loss of $6.8 million in the first quarter of 2022.
  • Adjusted EBITDA for the first quarter of 2023 was a loss of $6.4 million, compared to an adjusted EBITDA loss of $5.6 million in the first quarter of 2022.
  • CareDx is withdrawing 2023 revenue guidance at this time given a multitude of unknown variables related to the March and May 2023 Billing Article revisions.

Northwell Marks Milestone Surgery: More Than 100 Heart Transplants

Retrieved on: 
Wednesday, April 26, 2023
Hospitals, Health, Surgery, Cardiology, COPD, International Society for Heart and Lung Transplantation, Surgeon, HIV, Bakersfield Heart Hospital, Lung transplantation, DRS, Multimedia, Pulmonary fibrosis, North Shore University Hospital, Gold, MD, Patient, Nursing, Liver, Smoking, Family, Heart transplantation, Dentistry, Pharmaceutical industry, Heart, Northwell Health

View the full release here: https://www.businesswire.com/news/home/20230426005965/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230426005965/en/
    From left (seated): Heart transplant recipients Yvonne Johnson and Dr. James Jones; (top row): Drs.
  • “Northwell Health is the largest provider of health care in the region,” said Jeffrey Kuvin, MD , chair of cardiology at Northwell.
  • The Sandra Atlas Bass Heart Hospital here at NSUH is the quaternary cardiac hub of Northwell Health.
  • Please don’t hesitate – you could be saving a life.”
    Celebrating with their patients were: Aldo Iacono, MD , medical director of Lung Transplantation, Northwell; Maria Avila, MD, director of Heart Transplantation and Mechanical Support, Northwell; and Zachary Kon, MD , surgical director of Heart and Lung Transplantation, Northwell.

ISHLT and ISHLT Foundation Fund Research and Career Development with Grants

Retrieved on: 
Saturday, April 22, 2023
LV, Marker, Effect, Angiotensin, Survival, TN, Chloride, Doctor of Philosophy, II, NY, Cardiac allograft vasculopathy, Patient, Transport, Heart, Heart failure, ECP, International Society for Heart and Lung Transplantation, Research, MS, University of Texas Southwestern Medical Center, Longevity, TX, FAAN, Mallinckrodt, Montefiore Medical Center, Lung transplantation, Vanderbilt University Medical Center, Antibody, CAV, RN, Photopheresis, Partnership, International Consortium of Investigative Journalists, UT, Immunomodulation, Immunosuppression, Health literacy, International Society, Respiratory failure, Pharmaceutical industry, Nursing, Dietary supplement, Medical device, Cardiogenic shock

The grants were funded by the ISHLT Foundation, and announced at the 43rd ISHLT Annual Meeting & Scientific Sessions, held 19-22 April in Denver.

Key Points: 
  • The grants were funded by the ISHLT Foundation, and announced at the 43rd ISHLT Annual Meeting & Scientific Sessions, held 19-22 April in Denver.
  • These grants are the first of two 2023 ISHLT grant cycles.
  • “I am truly grateful for the strong industry support of our ISHLT research grants,” said Kathleen Grady, PhD, RN, MS, FAAN, Chair of the ISHLT Grants and Awards Committee, “which contribute to scientific breakthroughs in the areas of advanced heart and lung disease across the lifespan and career development of new investigators.
  • For more information about ISHLT and ISHLT Foundation Research Grants, visit ishlt.org/research-data/grants-awards/research-grants .

New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure

Retrieved on: 
Thursday, April 20, 2023
Exercise, Heart, Congestion, Duke University Hospital, Blood, Heart failure, HF, Physiology, CO, BVA, Colorado Convention Center, Anemia, International Society, CPET, Duke University Medical Center Patient Rapid Transit, International Society for Heart and Lung Transplantation, Blood volume, Health, Proxy, Medical imaging, Medical device, Patient

Oak Ridge, TN, April 20, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for advanced heart failure patients. Data were presented at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions, which brought together the world’s leading experts in heart and lung transplant held at the Colorado Convention Center, from April 19-22, in Denver, CO.

Key Points: 
  • In all three studies, Veraprapas Kittipibul, M.D., lead investigator used blood volume analysis (BVA) to measure the intravascular congestion and red cell status of heart failure (HF) patients, key metrics targeted to improve outcomes.
  • Highlights from the three studies included:
    “Differences in Pressure-Volume Relationship Between Obese and Non-Obese Patients with Advanced Heart Failure” - This prospective study examined the pressure-volume relationship using right heart catheterization to measure pressures, BVA and clinical assessment in obese heart failure patients.
  • Anemia is a common coexisting condition in patients with advanced heart failure.
  • Jonathan Feldschuh, Chief Scientific Officer at Daxor, said, “Heart failure management is centered around effective total blood and red blood cell volume management.